Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.

Autor: Budi HS; Department of Oral Biology, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia., Ahmad FN; University of Human Development, Sulaymaniyah, Kurdistan Region, Iraq., Achmad H; Department of Pediatric Dentistry, Faculty of Dentistry, Hasanuddin University, Makassar, Indonesia., Ansari MJ; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia., Mikhailova MV; Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia., Suksatan W; Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, 10210, Thailand., Chupradit S; Department of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand., Shomali N; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Marofi F; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. farooghmarofi@gmail.com.
Jazyk: angličtina
Zdroj: Stem cell research & therapy [Stem Cell Res Ther] 2022 Jan 29; Vol. 13 (1), pp. 40. Date of Electronic Publication: 2022 Jan 29.
DOI: 10.1186/s13287-022-02719-0
Abstrakt: Due to the overexpression or amplification of human epidermal growth factor receptor 2 (HER2) with poor prognosis in a myriad of human tumors, recent studies have focused on HER2-targeted therapies. Deregulation in HER2 signaling pathways is accompanied by sustained tumor cells growth concomitant with their migration and also tumor angiogenesis and metastasis by stimulation of proliferation of a network of blood vessels. A large number of studies have provided clear evidence that the emerging HER2-directed treatments could be the outcome of patients suffering from HER2 positive breast and also gastric/gastroesophageal cancers. Thanks to its great anti-tumor competence, immunotherapy using HER2-specific chimeric antigen receptor (CAR) expressing immune cell has recently attracted increasing attention. Human T cells and also natural killer (NK) cells can largely be found in the tumor microenvironment, mainly contributing to the tumor immune surveillance. Such properties make them perfect candidate for genetically modification to express constructed CARs. Herein, we will describe the potential targets of the HER2 signaling in tumor cells to clarify HER2-mediated tumorigenesis and also discuss recent findings respecting the HER2-specific CAR-expressing immune cells (CAR T and CAR NK cell) for the treatment of HER2-expressing tumors.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje